PostEra vs Abridge

Side-by-side comparison of AI visibility scores, market position, and capabilities

PostEra leads in AI visibility (80 vs 41)
PostEra logo

PostEra

LeaderHealthcare

General

SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.

AI VisibilityBeta
Overall Score
A80
Category Rank
#107 of 1158
AI Consensus
71%
Trend
up
Per Platform
ChatGPT
75
Perplexity
81
Gemini
76

About

PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.

Full profile
Abridge logo

Abridge

EmergingHealthcare

General

Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.

AI VisibilityBeta
Overall Score
C41
Category Rank
#777 of 1158
AI Consensus
50%
Trend
up
Per Platform
ChatGPT
35
Perplexity
49
Gemini
33

About

Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.

Full profile

AI Visibility Head-to-Head

80
Overall Score
41
#107
Category Rank
#777
71
AI Consensus
50
up
Trend
up
75
ChatGPT
35
81
Perplexity
49
76
Gemini
33
83
Claude
51
71
Grok
38

Key Details

Category
General
General
Tier
Leader
Emerging
Entity Type
company
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.